Enhancing Meningococcal Genomic Surveillance in the Meningitis Belt Using High-Resolution Culture-Free Whole-Genome Sequencing

J Infect Dis. 2022 Sep 4;226(4):729-737. doi: 10.1093/infdis/jiac104.

Abstract

Rollout of meningococcal serogroup A conjugate vaccine in Africa started in 2010, aiming to eliminate meningitis outbreaks, in meningitis belt countries. Since then, studies have been conducted, primarily using isolates, to assess the vaccine impact on the distribution of meningococcal strains in the region. Here, we implemented an innovative, culture-free whole-genome sequencing approach on almost 400 clinical specimens collected between 2017 and 2019 from meningococcal meningitis cases in 6 African countries. About 50% of specimens provided high-quality whole-genome sequence data for comprehensive molecular profiling of the meningococcal pathogen. Three major clonal complexes were identified: CC11 associated with serogroup W, CC181 associated with serogroup X, and CC10217 associated with serogroup C, which continues to rise as a predominant clonal complex in the region. Genomic surveillance for meningococcal meningitis can be significantly improved using culture-free methods to increase data representativeness and monitor changes in epidemiological landscape, especially for countries with low culture rate.

Keywords: Neisseria meningitidis; culture-free whole-genome sequencing; meningococcal meningitis surveillance; selective whole-genome amplification; targeted sequencing.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Genomics
  • Humans
  • Meningitis, Meningococcal* / epidemiology
  • Meningitis, Meningococcal* / prevention & control
  • Meningococcal Vaccines*
  • Neisseria meningitidis*
  • Vaccines, Combined
  • Vaccines, Conjugate

Substances

  • Meningococcal Vaccines
  • Vaccines, Combined
  • Vaccines, Conjugate